PCSA
HEALTHCAREProcessa Pharmaceuticals Inc
$2.75+0.09 (+3.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PCSA Today?
No stock-specific AI insight has been generated for PCSA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.76$19.62
$2.75
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-10.36
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume19K
Avg Volume (10D)—
Shares Outstanding2.7M
PCSA News
17 articles- Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 12, 2026
- Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Jan 9, 2026
- Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyYahoo Finance·Jan 5, 2026
- Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Dec 26, 2025
- Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims DeclineYahoo Finance·Dec 18, 2025
- Top Midday GainersYahoo Finance·Dec 17, 2025
- Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerYahoo Finance·Dec 17, 2025
- Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?Yahoo Finance·Dec 17, 2025
- Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025Yahoo Finance·Nov 5, 2025
- Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This WeekYahoo Finance·Aug 6, 2025
- Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Jul 18, 2025
- Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio ProgressYahoo Finance·Jul 11, 2025
- Processa Pharmaceuticals Provides Portfolio and Business UpdateYahoo Finance·Jul 1, 2025
- Processa Pharmaceuticals Announces Pricing of $7 Million Public OfferingYahoo Finance·Jun 17, 2025
- Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateYahoo Finance·Jun 17, 2025
- Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025Yahoo Finance·Jun 13, 2025
- Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingYahoo Finance·May 30, 2025
All 17 articles loaded
Price Data
Open$2.68
Previous Close$2.66
Day High$2.72
Day Low$2.62
52 Week High$19.62
52 Week Low$1.76
52-Week Range
$1.76$19.62
$2.75
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-10.36
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume19K
Avg Volume (10D)—
Shares Outstanding2.7M
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—